Last reviewed · How we verify
NCT03100240
The Mechanism of Modified Utral-long Protocol in Improving Endometrial Receptivity in Patients With PCOS and IR
NA trial testing Modified Supper Long Protocol in PCOS in 6 participants. Terminated before completion.
15 September 2018
Quick facts
| Lead sponsor | Reproductive & Genetic Hospital of CITIC-Xiangya |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 28 August 2017 |
| Primary completion | 15 September 2018 |
| Estimated completion | 30 September 2018 |
| Sites | 1 location across China |
Drugs / interventions tested
- Modified Supper Long Protocol
Conditions studied
- PCOS — all drugs for PCOS →
Sponsor
Reproductive & Genetic Hospital of CITIC-Xiangya
Who can join
Adults 20 to 35, female only, with PCOS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
NF-κB pathway activation-induced endometrial insulin resistance was one of the causes of infertility patients with PCOS and insulin resistance whose endometrial receptivity is declined .The investigators' previous findings indicated that the use of modified utral-long protocols ( GnRH-a was used twice in mid-luteal phaes) can improve clinical outcomes by improving endometrial receptivity in patients with PCOS , but the mechanism was not clear. Previous research also found that GnRH-a reduced the activity of NF-κB pathway in endometrial stromal cells and depended the dose and time.Thus, The investigators' subject will try to applicate GnRH-a to explore the influence of NF-κB pathway activity 、the state of insulin resistance and embryo implantation rate ;then we will investgate GnRH-a whether reduce NF-κB pathway activity-induced insulin resistance and ultimately improve endometrial receptivity by using GnRH-a in infertility patients with PCOS and insulin resistance.The investigators' research attempt to provide ideas for seeking inflammatory medication target in assisted reproductive technology in patients with PCOS by exploring the immune mechanism of GnRHa on improving the endometrial receptivity .
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03100240
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for PCOS
Currently open trials in the same condition.
- NCT06424860 — Fish Oil, Metformin and Heart Health in PCOS · Phase 1 · recruiting
- NCT06742710 — Liraglutide Treatment in Obese Infertile PCOS Women · Phase 4 · recruiting
- NCT07255911 — Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOS · NA · recruiting
- NCT06793072 — Adipokines in Polycystic Ovary Syndrome · recruiting
- NCT06591169 — Lifestyle Changes in PCOS with OSA and NAFLD · NA · recruiting
Other Reproductive & Genetic Hospital of CITIC-Xiangya trials
Trials by the same sponsor.
- NCT05227391 — Live Birth After Letrozole-stimulated Cycles Versus Hormone Replacement Treatment Cycles for the First Frozen Embryo Tra · NA · unknown
- NCT04639505 — Predictive Value of New AMH Test Method for Ovarian Response · completed
- NCT04538560 — Preimplantation Genetic Testing for Aneuploidy of Polar Bodies · NA · unknown
- NCT03910582 — Personalized FET in RIF Patients With Displaced Dating · NA · unknown
- NCT04178135 — Recombinant LH Supplementation Timing Strategies (From Day 1 or Day 6) to a Standard GnRH Agonist Long Protocol in Subse · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03100240 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Reproductive & Genetic Hospital of CITIC-Xiangya
- Last refreshed: 11 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03100240.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing